Definium Therapeutics (DFTX) had the highest return in 2020 by a mid-cap US stock, returning 5,346.4%.
| ASSET | YEAR | % RETURN |
|---|---|---|
Definium Therapeutics (DFTX) | 2020 | 5,346.43% |
Novavax (NVAX) | 2020 | 2,694.74% |
Ondas (ONDS) | 2020 | 1,999.46% |
Riot Platforms (RIOT) | 2020 | 1,390.35% |
Nio Inc Class A ADR (NIO) | 2020 | 1,088.78% |
Chord Energy (CHRD) | 2020 | 1,026.42% |
Plug Power (PLUG) | 2020 | 956.39% |
Celsius (CELH) | 2020 | 941.61% |
Celldex Therapeutics (CLDX) | 2020 | 682.14% |
Enphase Energy (ENPH) | 2020 | 565.42% |
CleanSpark (CLSK) | 2020 | 440.46% |
Peloton Interactive (PTON) | 2020 | 424.98% |
Skeena Resources (SKE) | 2020 | 400% |
Applied Digital (APLD) | 2020 | 389.35% |
Denali Therapeutics (DNLI) | 2020 | 376.99% |
TG Therapeutics (TGTX) | 2020 | 368.23% |
Innodata (INOD) | 2020 | 364.91% |
Bilibili (BILI) | 2020 | 340.27% |
Acm Research (ACMR) | 2020 | 333.8% |
DraftKings (DKNG) | 2020 | 331.51% |
Appian (APPN) | 2020 | 319.16% |
Cogent Biosciences (COGT) | 2020 | 279.39% |
Calix (CALX) | 2020 | 272% |
Scholar Rock (SRRK) | 2020 | 264.34% |
Magnite (MGNI) | 2020 | 264.29% |
Mid-cap stocks are treated as having a market cap between $2B and $10B.